When evaluating new technology, the most critical initial question is not what it can do, but what it *cannot* do. Understanding a tool's boundaries and limitations is essential for appropriate application, building trust with users and regulators, and achieving real-world validation.
A venture capital partner reveals a specific evaluation framework focusing on seven key areas: Team, Total Addressable Market (TAM), Traction, Technology, Transformation (industry impact), Timing (why now?), and the potential for a 10x return. This provides a clear roadmap for founders seeking funding.
Experts advise platform technology founders to resist showcasing broad applicability. Instead, they should focus on specific use cases where they can generate compelling evidence, such as for a particular disease or drug modality. This builds credibility and creates a "beachhead" for future expansion.
Despite the buzz, a clinical development expert cautions that AI's impact in drug development is limited. The primary bottleneck isn't the algorithms but the lack of sufficient, high-quality human biological data that can be translated into reliable predictions, as animal models often fail to provide it.
A pharma commercial expert suggests a long-term go-to-market strategy focused on education. By working with universities and corporate training departments, a new technology platform can create a "new breed of researchers" who become early evangelists and future champions for the technology within their organizations.
For new technologies to gain adoption in pharma, the central value proposition must be about de-risking decisions. Leaders and regulators often view the technology as a "black box" and are less concerned with its mechanics than with its ability to give them confidence in making safer, more reliable choices.
The high failure rate of drugs in human trials after passing animal tests stems from a fundamental biological reality: a "mouse is not a small human." This "structural mismatch" is especially severe for modern, human-specific therapies like CAR-T and RNA, rendering animal models poor proxies.
For complex technologies like Transel's DART platform, the most effective sales strategy is demonstrating value directly through proof-of-concept (POC) projects. Successful POCs naturally lead to larger paid work orders and create internal advocacy within client organizations, creating a powerful pull effect.